MTOR and neoplasm: The synergistic growth inhibition of everolimus/vinorelbine may be explained, at least in part, by blood-vessel normalization, which aids in the delivery of the drugs to the tumor cells, resulting in the downregulations of the mTOR-signaling pathway, survivin, and cell-cycle regulators, as well as an increase in apoptosis.